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BACKGROUND: Carriers of germline mutations in DNA mismatch repair (MMR) genes have a high risk of colorectal cancer (CRC), but
the modifiers of this risk are not well established. We estimated an association between body mass index (BMI) in early adulthood
and subsequent risk of CRC for carriers and, as a comparison, estimated the association for non-carriers.
METHODS: A weighted Cox regression was used to analyse height and weight at 20 years reported by 1324 carriers of MMR gene
mutations (500 MLH1, 648 MSH2, 117 MSH6 and 59 PMS2) and 1219 non-carriers from the Colon Cancer Family Registry.
RESULTS: During 122304 person-years of observation, we observed diagnoses of CRC for 659 carriers (50%) and 36 non-carriers
(3%). For carriers, the risk of CRC increased by 30% for each 5kgm
–2increment in BMI in early adulthood (hazard ratio, HR: 1.30;
95% confidence interval, CI: 1.08–1.58; P¼0.01), and increased by 64% for non-carriers (HR: 1.64; 95% CI: 1.02–2.64; P¼0.04)
after adjusting for sex, country, cigarette smoking and alcohol drinking (and the MMR gene that was mutated in carriers). The
difference in HRs for carriers and non-carriers was not statistically significant (P¼0.50). For MLH1 and PMS2 (MutLa heterodimer)
mutation carriers combined, the corresponding increase was 36% (HR: 1.36; 95% CI: 1.05–1.76; P¼0.02). For MSH2 and MSH6
(MutSa heterodimer) mutation carriers combined, the HR was 1.26 (95% CI: 0.96–1.65; P¼0.09). There was no significant
difference between the HRs for MutLa and MutSa heterodimer carriers (P¼0.56).
CONCLUSION: Body mass index in early adulthood is positively associated with risk of CRC for MMR gene mutation carriers and non-
carriers.
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Lynch syndrome, historically known as hereditary non-polyposis
colorectal cancer (Jass, 2006), refers to colorectal and other
cancers caused by germline mutations in DNA mismatch repair
(MMR) genes MLH1, MSH2, MSH6 and PMS2 (Vasen et al, 1999).
Approximately 1 in 3000 people in the general population carry a
mutation in an MMR gene (Dunlop et al, 2000). These MMR gene
mutation carriers are at substantially increased risk of colorectal
cancer (CRC) with an estimated cumulative risk to age 70 years
between 40% and 70% depending on the carrier’s sex and the
MMR gene that is mutated (Chen et al, 2006; Jenkins et al, 2006;
Senter et al, 2008; Baglietto et al, 2010). Physical characteristics
or environmental exposures of the mutation carriers could
also modify their risks of developing CRC (Jenkins et al, 2007).
Identifying modifiers of CRC risk for carriers of MMR gene
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ymutations is important for understanding carcinogenesis. Identi-
fying potentially protective or harmful and avoidable risk factors
also creates opportunities for mutation carriers to reduce their
risks of life-threatening diseases.
Previous studies have provided evidence for the existence of
modifiers of CRC risk for MMR gene mutation carriers. For
example, CRC risk for carriers is positively associated with alcohol
consumption (Watson et al, 2004) and negatively associated
with fruit consumption and dietary fibre intake (Diergaarde et al,
2007). For smoking, CRC risk for carriers is positively associated
with current smoking (Diergaarde et al, 2007; Pande et al, 2010),
but negatively or not associated with former smoking (Diergaarde
et al, 2007; Pande et al, 2010). However, the association between
body size and CRC risk for MMR gene mutation carriers is yet to
be established.
One CRC risk factor for people in the general population is body
size, a collective term for body mass index (BMI), waist
circumference and height (Dai et al, 2007; Larsson and Wolk,
2007; Moghaddam et al, 2007; Renehan et al, 2008). Previous case–
control studies of CRC cases with a family history (therefore, likely
to be enriched for MMR gene mutation carriers) compared with
population-based controls who were unselected for family history,
have shown that current BMI is positively associated with CRC
risk (Slattery et al, 2003; Campbell et al, 2007). However, studies
that have examined the association between current BMI and the
occurrence of tumours with microsatellite instability (MSI), a
common characteristic of CRCs caused by MMR defects, have
reported no statistically significant associations with this form of
disease (Slattery et al, 2000; Campbell et al, 2010). One study that
examined the association between BMI and colorectal adenoma
risk for MMR gene mutation carriers observed a positive associ-
ation for males but not females (Botma et al, 2010).
Identifying an association of BMI in early adulthood on sub-
sequent cancer risk would be important for MMR gene mutation
carriers who learn their mutation status as adults in their 20s, an
increasingly common occurrence because of increased systematic
testing in the population, with the consequent opportunity to
reduce their risk of disease. In this study, we estimated an
association between BMI at age 20 years and CRC risk for MMR
gene mutation carriers. As a comparison, we also estimated the
association for non-carriers to investigate whether BMI has a
differential effect on risk for CRC by mutation status.
MATERIALS AND METHODS
Recruitment
Subjects comprised carriers and non-carriers of pathogenic
mutations (see below) in the MMR genes MLH1, MSH2, MSH6
and PMS2, recruited and genetically characterised by the Colon
Cancer Family Registry (Colon CFR). Study designs and recruit-
ments for the Colon CFR can be found at http://epi.grants.
cancer.gov/CFR/ and have been published in detail (Newcomb
et al, 2007). Probands were either a recently diagnosed CRC case
reported to a population-complete cancer registry or an attendee at
a family cancer clinic. They were recruited between 1997 and 2007
and ascertained from family cancer clinics from Australia
(Melbourne, Adelaide, Perth, Brisbane and Sydney), New Zealand
(Auckland) and the United States (Mayo Clinic, Rochester,
Minnesota and Cleveland) or from population-complete cancer
registries in the United States (Puget Sound, Washington State; the
State of Minnesota; Los Angeles, California; Arizona; Colorado;
New Hampshire; North Carolina; and Hawaii), Australia (Victoria)
and Canada (Ontario).
Probands were asked for permission to contact their relatives to
seek their enrolment in the Colon CFR. For probands ascertained
from family cancer clinics, there were pre-specified rules
consistent across recruiting centres governing which relatives
were to be approached for recruitment (Newcomb et al, 2007). For
probands ascertained from population-complete cancer registries,
first-degree relatives were recruited at all centres and in some
centres, recruitment extended to more distant relatives. Written
informed consent was obtained from all study participants, and the
study protocol was approved at each Colon CFR centre.
Data collection
At recruitment, baseline information on demographics, personal
characteristics, personal and family history of cancer, cancer
screening history, history of polyps, polypectomy and other
surgery were obtained from all participants. Participants were
followed-up approximately 5 years after baseline to update all
this information. The questionnaires are available from http://
cfrisc.georgetown.edu/isc/dd.questionnaires.do. Reported cancer
diagnoses and age at diagnoses were confirmed, where possible,
using pathology reports, medical records, cancer registry reports
and/or death certificates. Blood samples and tumour tissues were
collected for genetic testing. The present study was based on all
available baseline and follow-up data.
Self-reported height and weight at approximately age 20 years
were collected using standardised personal interviews (University
of Southern California Consortium), telephone interviews
(University of Southern California Consortium, Fred Hutchinson
Cancer Research Centre and University of Melbourne) or mailed
questionnaires (University of Hawaii, Cancer Care Ontario and
Mayo Clinic).
Mutation screening and testing
Testing for MLH1, MSH2, MSH6 and PMS2 mutations was
performed for all case probands ascertained from family cancer
clinics and for all probands from population-based ascertainment
who had a colorectal tumour displaying evidence of impaired
MMR function as evidenced by either MSI, or by lack of MMR
protein expression by immunohistochemistry. Mutation testing
was performed by Sanger sequencing or denaturing high-pressure
liquid chromatography, followed by confirmatory DNA sequen-
cing. Large insertion and deletion mutations were detected by
multiplex ligation-dependent probe amplification according to the
manufacturer’s instructions (MRC Holland, Amsterdam, The
Netherlands) (Southey et al, 2005; Newcomb et al, 2007; Senter
et al, 2008). All participants who donated a blood sample, and who
were relatives of probands with a pathogenic mutation, underwent
testing for the same mutation identified in the proband.
Study sample
For this study, we included male and female probands and their
participating relatives who were confirmed carriers and confirmed
non-carriers of an MMR gene mutation. In total, 1468 carriers and
1365 non-carriers were identified. Of these, 144 (10%) carriers and
146 (11%) non-carriers were excluded due to missing data on
height or weight at age 20 years, leaving a total of 1324 carriers
(252 from population-based sources) and 1219 non-carriers (109
from population-based sources) for the analysis. Excluded subjects
did not differ in baseline characteristics from subjects who entered
into the analyses (age, sex, country and gene mutated) (data not
shown).
We were unable to analyse current BMI in this study, as it was
not available 1–2 years prior to diagnosis or censored age for 833
subjects (636 carriers and 197 non-carriers), which is 33% of the
total sample size. This was composed of 450 CRC cases (425
carriers and 25 non-carriers), 215 subjects (140 carriers and 75
non-carriers) with another cancer and 164 subjects with a prior
polypectomy (70 carriers and 94 non-carriers) and 4 subjects
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at last contact.
Definitions
A pathogenic mutation was defined to be a variant that was
predicted to result in a stop codon, a frameshift mutation, a large
insertion or deletion, or a missense mutation previously reported
in the scientific literature to be pathogenic. Age at CRC was the age
at first diagnosis of CRC. Height and weight were defined as self-
reported height and weight at age 20 years, respectively. BMI at
age 20 years was calculated as weight as reported at age 20 years
in kilograms divided by height in metres squared (kgm
–2).
Body mass index was categorised as p18.49kgm
–2(underweight),
18.50–24.99kgm
–2 (normal weight), 25.00–29.99kgm
–2 (over-
weight) or X30.00kgm
–2 (obese) according to World Health
Organization criteria (World Health Organization, 1998). T and N
staging of CRC was categorised according to the American Joint
Committee on Cancer staging (Edge et al, 2009).
Statistical analysis
Mismatch repair gene mutation carriers and non-carriers were
treated as a cohort from birth. A proportional Cox regression
model with age as the time scale was used to estimate hazard ratios
(HR) relating BMI to CRC risk for carriers and non-carriers. Time
at risk started at birth and ended at age of diagnosis of cancer of
any site, polypectomy, death or last contact, whichever occurred
first. The rationale for censoring at diagnosis of any cancer was
that the resultant treatment and surveillance might alter risk of
subsequent cancers, including CRC and this would introduce
bias if the first cancer was associated with body size. Similarly,
as polypectomy may reduce CRC risk, censoring at time of
polypectomy was also required to avoid potential bias. Of the total
1324 mutation carriers, observation time ended at age of diagnosis
for 659 CRC cases, and was censored at age of polypectomy for 173
subjects, at age of diagnosis of another cancer for 144 subjects, at
age of death for 4 subjects and at age of last contact for 344
subjects. Of the total 1219 non-carriers, time of observation ended
at the age of diagnosis for 36 CRC cases, at age of polypectomy for
176 subjects, at age of diagnosis of another cancer for 101 subjects,
at age of death for 14 subjects and at age of last contact for
892 subjects.
Since some subjects were ascertained because they were from
multiple-case CRC families, and CRC cases were preferentially
tested for MMR gene mutations, the selection of subjects was not
random with respect to disease status. To adjust for this non-
random ascertainment, we used the weighted cohort approach
described by Antoniou et al (2005), which has been used for
modifier studies of cancer risk for carriers of rare genetic
mutations (e.g., Andrieu et al, 2006; Antoniou et al, 2008; Win
et al, 2011). A simulation study of this approach (Antoniou et al,
2005) showed that allowing for non-random sampling of subjects
by using rates from an external referent population removed bias
when the external rates were correctly specified, and reduced bias
if the external rates were not completely accurate.
Age-specific incidence rates of CRC for MMR gene mutation
carriers were previously estimated as described in detail by Pande
et al (2010). These age-specific incidence rates were used to
calculate sampling fractions to weight the proportion of affected
and unaffected carriers in each age stratum, so that the proportion
of affected carriers in each age group equalled the population
proportions (Supplementary Table S1).
Due to the rarity of mutations in the population, age-specific
incidence rates for non-carriers were assumed to equal those for
the general population. Data on age-specific (5-year intervals)
population cancer incidence rates were obtained from the
American Cancer Society Cancer Facts and Figures 2008
(American Cancer Society, 2008). Using these age-specific incidence
rates, we calculated sampling fractions to weight the proportion of
affected and unaffected non-carriers in each age stratum.
Body mass index was fitted as a continuous variable and as a
categorical variable based on WHO BMI classification (World
Health Organization, 1998). In order to determine whether a non-
linear association with a continuous variable was a superior fit
compared with a linear model, we fitted and compared fractional
polynomial models. Models were compared using Wald’s tests.
The proportional hazards assumption was tested by examining
the relationship between the scaled Schoenfeld residuals and
survival time.
To control for potential confounders present at the age at which
BMI was reported (i.e., 20 years old), we adjusted for (i) sex,
(ii) country of recruitment, (iii) cigarette smoking at age 20 (never,
ever) and (iv) alcohol drinking at age 20 (ever, never) in both
carriers and non-carriers, and further adjusted for (v) specific
MMR gene that was mutated in carriers. Interactions between
(i) mutation carrier status and BMI, (ii) sex and BMI and (iii) the
specific MMR gene mutated and BMI were tested by adding an
interaction term in a multivariable model. We did not adjust
for current BMI because of the well-known bias introduced by
adjusting for variables that are in the causal pathway or partly
caused by the exposure of interest. The associations between BMI
and CRC risk were estimated separately for carriers of mutation
in each MMR gene, and carriers of mutations in the MutLa
heterodimer (MLH1 and PMS2) and MutSa heterodimer (MSH2
and MSH6) genes.
Two sensitivity analyses were conducted: (i) to determine
whether unverified self-reported CRC cases or cases reported by
relatives influenced the associations with BMI, we performed
analyses after excluding these cases and (ii) to determine whether
censoring at polypectomy influenced the associations with BMI, we
performed analyses of colorectal neoplasia that is CRC and
colorectal polyps combined, as the outcome.
We applied the Huber–White robust variance estimation by
clustering on family membership to allow for any correlation of
risk between family members (Rogers, 1993; Williams, 2000). All
statistical tests were two sided and, following convention,
statistical significance for testing a predetermined null hypothesis
was set at Po0.05. All statistical analyses were performed using
Stata 10.0 (StataCorp, 2007).
RESULTS
The study comprised 1324 carriers (737 females) of MMR gene
mutations (500 in MLH1, 648 in MSH2, 117 in MSH6 and 59 in
PMS2) from 498 families contributing a total of 58868 person-
years, of which 659 (50%) were diagnosed with CRC, and 1219
non-carriers (712 females) from 287 families contributing 63436
person-years, of which 36 (3%) were diagnosed with CRC. Of all
participants, 839 carriers and 983 non-carriers (72%) were
recruited in Australia or New Zealand, 367 carriers and 199 non-
carriers (22%) in the United States and 118 carriers and 37 non-
carriers (6%) in Canada. Baseline characteristics of the study
subjects are summarised in Table 1.
Of the 659 CRC cases in carriers, 595 (90%) were confirmed by
pathology report or review, SEER or other cancer registries, or
hospital or clinical records and 64 (10%) were unconfirmed
reports by self or relatives (Table 2). The mean age at CRC
diagnosis was 44 (s.d.: 11) years for carriers and 57 (s.d.: 15) years
for non-carriers. The mean reported BMI at age 20 years was 22.7
(s.d.: 3.9) kgm
–2 for carriers and 22.4 (s.d.: 3.7) kgm
–2 for non-
carriers. There were no significant differences in mean BMI or the
distributions of mutated MMR genes by country (data not shown).
Table 3 shows that carriers who were obese (X30kgm
–2) had
an approximately two-fold (HR: 2.35; 95% confidence interval,
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had normal BMI (18.5–24.99kgm
–2). Colorectal cancer risk for
carriers was estimated to be 30% higher for each increment of
5kgm
–2 in BMI (adjusted HR: 1.30; 95% CI: 1.08–1.58; P¼0.01).
The corresponding HR for female carriers was 1.28 (95% CI: 0.98–
1.69; P¼0.08) and for male carriers was 1.33 (95% CI: 1.01–1.76;
P¼0.04); there was no statistically significant evidence that these
HRs were different between men and women (P¼0.97).
The HR per 5kgm
–2 in BMI was 1.20 (95% CI: 0.99–1.44;
P¼0.06) for right-sided colon cancers; 1.03 (95% CI: 0.84–1.27;
P¼0.76) for left-sided colon and rectosigmoid cancers; and 1.31
(95% CI: 0.84–2.05; P¼0.24) for rectal cancers. When a fractional
polynomial model was fitted, there was no evidence that the (log)
HR was non-linear (P¼0.72).
Table 4 presents separate results for carriers of mutations in
each MMR gene. There was a positive association between BMI
and CRC risk for MLH1 and PMS2 (MutLa heterodimer) mutation
carriers combined (HR: 1.36; 95% CI: 1.05–1.76; P¼0.02). The HR
for MSH2 and MSH6 (MutSa heterodimer) mutation carriers
combined was 1.26 (95% CI: 0.96–1.65; P¼0.09), and not
statistically different from the HR for MutLa heterodimer mutation
carriers (P¼0.56).
For non-carriers of MMR gene mutations, CRC risk was
estimated to be 64% higher for each increment of 5kgm
–2
in BMI (adjusted HR: 1.64; 95% CI: 1.02–2.64; P¼0.04).
The corresponding HR for female carriers was 1.40 (95% CI:
0.67–2.91; P¼0.37) and for male carriers was 1.82 (95% CI:
0.93–3.53; P¼0.08); the difference between sexes was not statis-
tically significant (P¼0.32). When a fractional polynomial model
was fitted, there was no evidence that the (log) HR was non-linear
(P¼0.88).
The HRs for carriers and non-carriers were not statistically
different (interaction between mutation status and BMI; P¼0.50).
Sensitivity analyses showed that (i) after excluding unverified
self-reported cases or cases reported by relatives, the adjusted HR
for each 5kgm
–2 increment in BMI was 1.37 (95% CI: 1.13–1.66;
P¼0.002) for carriers and 1.65 (95% CI: 0.97–2.80; P¼0.06) for
non-carriers and (ii) defining the outcome as colorectal neoplasia
(either CRC or polyp), the adjusted HR for each 5kgm
–2
increment in BMI was 1.20 (95% CI: 1.00–1.44; P¼0.05) for
carriers and 1.27 (95% CI: 0.96–1.66; P¼0.09) for non-carriers.
DISCUSSION
We have shown that greater BMI at age 20 years is associated with
a higher risk of CRC in later life for both carriers and non-carriers
of pathogenic germline mutations in MMR genes. For MMR
Table 1 Baseline characteristics of study subjects (MMR gene mutation carriers and non-carriers)
Mutation carriers Non-carriers
CRC-affected
(N¼659)
number (%)
CRC-unaffected
(N¼665)
number (%)
CRC-affected
(N¼36)
number (%)
CRC-unaffected
(N¼1183)
number (%)
Sex
Female 332 (50) 405 (61) 19 (53) 693 (59)
Age (year)
a, mean (s.d.) 44.0 (11.1) 44.9 (13.7) 56.8 (14.8) 51.9 (15.6)
MMR gene mutated
MLH1 273 (41) 227 (34)
MSH2 308 (47) 340 (51)
MSH6 40 (6) 77 (12)
PMS2 38 (6) 21 (3)
Country of recruitment
Australia or New Zealand 355 (54) 484 (72) 16 (44) 967 (81)
USA 216 (33) 151 (23) 15 (42) 184 (16)
Canada 88 (13) 30 (5) 5 (14) 32 (3)
Source of recruitment
Clinic based 473 (72) 599 (90) 23 (64) 1087 (92)
Population based 186 (28) 66 (10) 13 (36) 96 (8)
Cigarette smoking
b
Never 319 (49) 363 (55) 15 (44) 652 (55)
Ever 338 (51) 299 (45) 19 (56) 527 (45)
Unknown 2 3 2 4
Alcohol consumption
c
Never 233 (36) 193 (31) 16 (44) 417 (36)
Ever 408 (64) 439 (69) 20 (56) 732 (64)
Unknown 18 33 0 34
Body size, mean (s.d.)
Height (cm) 170.1 (10.1) 169.8 (9.7) 169.7 (9.5) 169.4 (9.9)
Weight at age 20 (kg) 66.9 (15.5) 65.4 (14.6) 65.8 (13.0) 64.6 (13.8)
BMI at age 20 (kgm
–2)
d 23.0 (4.0) 22.5 (3.7) 22.7 (3.3) 22.4 (3.7)
Abbreviations: BMI¼body mass index; CRC¼colorectal cancer; MMR¼mismatch repair.
aAge at first diagnosis of CRC for affected subjects; age at first polypectomy or
diagnosis of another cancer or last contact for unaffected subjects (whichever came first).
bCigarette smoking status at age 20 years; cigarette smoking was defined as ever
smoking one cigarette per day for 3 months or longer.
cAlcohol consumption status at age 20 years; alcohol beverages include beer, wine, cider, spirits, mixed drinks or cocktails.
dCalculated from self-reported height and weight at age 20 years.
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between the strengths of association for men and women, and for
carriers of mutations in MutLa or MutSa heterodimer genes. These
results suggest that BMI in early adulthood is a potential modifier
of CRC risk in later life for MMR gene mutation carriers as a
whole.
Our study was based on 1324 carriers and 1219 non-carriers of a
confirmed pathogenic mutation in any of four MMR genes, making
it the largest study to date of this issue. To overcome bias when
subjects are selected on the basis of phenotype, we used a weighted
cohort approach (Antoniou et al, 2005), which has been
successfully utilised for studies of modifiers of cancer risk of rare
genetic mutations (e.g., Andrieu et al, 2006; Antoniou et al, 2008;
Win et al, 2011). Familial correlation in the risk of CRC was also
accounted for using a robust variance estimation to derive
appropriate measure of HR estimate imprecision (Rogers, 1993;
Williams, 2000). Another strength was the standardised and
uniformly high-quality testing for MMR gene mutations by the
Colon CFR (Newcomb et al, 2007).
Potential limitations of this study include the use of self-
reported weight and height and the often long period between age
20 years and the interview, meaning that participants often had to
recall weight many years in the past. However, other studies have
shown that measures of weight taken at age 20–30 years are well
correlated with recalled values at age 50–70 years, with correlation
coefficients ranging between 0.73 and 0.95 (Stevens et al, 1990;
Perry et al, 1995; Troy et al, 1995; Norgan and Cameron, 2000;
Tamakoshi et al, 2003). There is a possibility of response bias,
where CRC-affected subjects recall their weight at age 20 years
differently than unaffected subjects. It is also possible that the
recall of weight at age 20 years may have depended on the methods
of data collection, which varied by recruitment centre, and,
therefore, may have resulted in decreased precision of reported
weight data. Since cases with poor survival were less likely to be
included in this analysis (as they were unable to provide a blood
sample for genetic testing and complete a questionnaire), there
is a possibility of survival and selection bias if age at onset and
survival of cases were related to BMI and/or mutation status. We
acknowledge that exposures such as physical activity and meat
consumption that we have not adjusted for in this analysis may be
confounders for the observed associations.
One previous study investigated the role of BMI in colorectal
neoplasms for MMR gene mutation carriers, but the focus of their
study was colorectal adenomas (Botma et al, 2010). They reported
that MMR gene mutation carriers who are overweight or obese
(current BMI X25kgm
–2) had higher risk of adenomas compared
with those with normal BMI (o25kgm
–2) for men (HR: 8.72;
Table 2 Source of colorectal cancer diagnoses verifications and tumour
characteristics
Carriers
number (%)
Non-carriers
number (%)
Source of verification
Pathology review/report 569 (86) 25 (69)
SEER/other cancer registry 17 (3) 0 (0)
Hospital or clinic record 9 (1) 1 (3)
Self/relative 64 (10) 10 (28)
Tumour site
Right
a 356 (61.1) 15 (58)
Left
b 119 (20.4) 6 (23)
Rectosigmoid 30 (5.1) 2 (8)
Rectum 78 (13.4) 3 (11)
Unknown 76 10
Histology grade
Well differentiated 46 (10) 1 (5)
Moderately differentiated 279 (62) 14 (74)
Poorly differentiated 124 (28) 4 (21)
Unknown 210 17
AJCC stage
c
I 122 (28) 4 (2.5)
II (A, B, C) 214 (50) 9 (53)
III (A, B, C) 94 (22) 4 (23.5)
Unknown 229 19
Synchronous
Yes 44 (12) 2 (11)
No 313 (88) 17 (89)
Unknown 302 17
Abbreviation: AJCC¼American Joint Committee on Cancer.
aRight colon included
caecum, ascending colon, hepatic flexure and transverse colon.
bLeft colon included
splenic flexure, descending colon and sigmoid colon.
cMetastasis status was
unavailable; and any of this stage could be stage IV.
Table 3 Hazard ratios for association between BMI at age 20 years and CRC risk for MMR gene mutation carriers and non-carriers
Total
number
Total
person-years
CRC
number (%)
Univariable analysis Multivariable analysis
HR (95% CI)
a P HR (95% CI)
a,b P
Carriers
BMI (per 5kgm
–2) 1324 58868 659 (50) 1.33 (1.11–1.58) 0.002 1.30 (1.08–1.58) 0.007
WHO classification
Underweight 121 5353 54 (45) 0.91 (0.60–1.38) 1.04 (0.66–1.64)
Normal 909 41014 450 (50) 1.00 (referent) 1.00 (referent)
Overweight 233 9971 118 (51) 1.17 (0.83–1.63) 0.01 1.12 (0.78–1.62) 0.06
Obese 61 2530 37 (61) 2.40 (1.35–4.27) 2.35 (1.30–4.23)
Non-carriers
BMI (per 5kgm
–2) 1219 63436 36 (3) 1.86 (1.24–2.77) 0.002 1.64 (1.02–2.64) 0.04
WHO classification
Underweight 113 6157 3 (3) 0.81 (0.23–2.88) 1.01 (0.28–3.73)
Normal 904 47641 25 (3) 1.00 (referent) 1.00 (referent)
Overweight 158 7694 6 (4) 3.28 (1.09–9.84) 0.01 3.62 (1.05–12.55) 0.05
Obese 44 1944 2 (5) 4.98 (1.17–21.23) 3.00 (0.60–14.97)
Abbreviations: BMI¼body mass index; CI¼confidence interval; CRC¼colorectal cancer; HR¼hazard ratio; MMR¼mismatch repair.
aWith robust variance estimation for familial
correlation in risk.
bAdjusted for sex, country, cigarette smoking and alcohol drinking in both carriers and non-carriers; and further adjusted for specific MMR gene mutated in carriers.
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0.19–3.07). A case–control study of CRC cases who met the
revised Bethesda or Amsterdam criteria for Lynch syndrome and
population controls observed both increased BMI at age 20 years
and current BMI were associated with increased CRC risk for men,
but not for women (Campbell et al, 2007). In our study, we did not
observe statistical evidence for a difference between men and
women for associations of BMI with CRC risk. Consistent with our
results, Slattery et al (2003) found that obese people with a family
history of CRC had approximately two-fold increased risk of CRC
compared with those with normal BMI for both sexes combined
(odds ratio: 1.65, 95% CI: 1.01–2.73).
There have been two population-based case–control studies
examining the association between BMI and CRC with and without
MSI, a phenotype that indicates loss of MMR function somatically,
but not necessarily due to inherited mutations. Approximately
50% of CRCs with MSI diagnosed before age 50 years arise in MMR
gene mutation carriers and 12% of cases diagnosed at age X50
years are MMR gene mutation carriers (Hampel et al, 2008). These
studies found positive associations between current BMI and
microsatellite stable tumours, but no association with MSI-high
tumours (Slattery et al, 2000; Campbell et al, 2010). It is difficult to
compare these findings with our results because MSI tumours
include CRCs caused not by an inherited MMR gene mutation but
by methylation of MLH1 (Herman et al, 1998; Poynter et al, 2008),
and, therefore, these previous studies are probably not gener-
alisable to MMR gene mutation carriers. Using the population-
based cases from the Colon CFR (the same source of data for this
analysis), Campbell et al (2010) found some suggestion that obese
MMR gene mutation carriers, compared with those with normal
BMI, had an increased risk of CRC (odds ratio: 3.96; 95% CI:
0.59–26.48) when MSI-high was further stratified by known MMR
gene mutation status. As evidenced by the broad CIs, however,
the study had insufficient numbers (only 85 carriers) to adequately
investigate the association between BMI and CRC due to MMR
gene mutations.
We observed a statistically significant association between BMI
in early adulthood and CRC risk for MLH1 and PMS2 mutation
carriers, but not for MSH2 and MSH6 mutation carriers. However,
the associations were not statistically different from each other
(P¼0.51). The proteins produced by MSH2 and MSH6 from the
MutSa heterodimer are responsible for detecting DNA mismatches
occurring during replication, whereas the proteins produced by
MLH1 and PMS2 from the MutLa heterodimer are responsible for
cleavage (Kadyrov et al, 2006; Hewish et al, 2010). The association
we observed with MLH1 and PMS2 mutations is consistent
with obesity affecting CRC risk by inducing a second hit in the
remaining wild-type allele of MLH1 or PMS2. It is also consistent
with obesity being a tumour promoter that is more relevant to
tumours induced by MMR defects due to mutations in the MutLa
heterodimer.
In this study, as all non-carriers are relatives of mutation
carriers and, therefore, in general matched for familial factors that
may be risk factors for CRC, the two groups are comparable. Given
that we observed similar associations of BMI with CRC risk for
carriers and non-carriers, we can surmise that having a mutation
in an MMR gene does not alter the degree of increased risk
imposed by BMI in early adulthood. In contrast, we have shown,
using the same analytical design and data source, that non-carrier
women were 74% more likely to develop endometrial cancer
for every 5kgm
–2 increase in BMI at age 20 (HR: 1.74; 95% CI:
1.27–2.37; Po0.001), while carriers were not more likely to
develop endometrial cancer with increased BMI (Win et al, 2011).
Given MMR mutation carriers are rare in the general population
(Dunlop et al, 2000), the vast majority of the general population
are non-carriers and, therefore, our finding for non-carriers will be
generalisable to the general population. Our findings for non-
carriers are consistent, in terms of direction, with previously
published studies that observed a positive association between
BMI in early adulthood and subsequent CRC risk for the general
population (Le Marchand et al, 1992; Lee and Paffenbarger, 1992;
Must et al, 1992; Russo et al, 1998).
The biologic mechanisms underlying an association between
body size in early adulthood and increased risk of CRC are not well
understood. One theory suggests that obesity, particularly central
obesity, increases insulin resistance and hyperinsulinaemia
(Giovannucci, 1995; Kahn and Flier, 2000) via alterations in the
signalling of endogenous hormones, particularly not only insulin
and insulin-like growth factors, but also steroid hormones, and
possibly, adipocyte-derived factors such as leptin and adiponectin
(Gunter and Leitzmann, 2006; John et al, 2006). High circulating
concentrations of insulin and C-peptide, as well as type 2 diabetes,
are associated with increased risk of CRC (Kaaks et al, 2000;
Larsson et al, 2005). It is of interest that MMR defects frequently
result in mutations of the insulin-like growth factor receptor
(IGFR), which involves this same insulin signalling system (Duval
and Hamelin, 2002). It is not known if the effect of obesity in MMR
gene mutation carriers is related to IGFR mutational events.
Our results suggest that BMI in early adulthood is a potential
modifier of CRC risk for carriers of an MMR gene mutation.
Currently, the only methods available for MMR gene mutation
carriers to reduce their risk for CRC are screening by colonoscopy
(de Jong et al, 2006), prophylactic subtotal colectomy (Smith and
Rodriguez-Bigas, 2009) and aspirin chemoprevention (Burn et al,
2009). Avoiding obesity in early adulthood might also reduce the
risk of CRC for MMR gene mutation carriers.
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